Alkylation of amines with allylic alcohols and deep eutectic solvents as metal-free and green promoters

Sthephany Zárate-Roldán,^{a,b} M. Concepción Gimeno*^b and Raquel P. Herrera*^a

^a Laboratorio de Organocatálisis Asimétrica, Departamento de Química Orgánica. Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza. C/ Pedro Cerbuna 12, E-50009 Zaragoza, Spain. <u>raquelph@unizar.es</u>

^b Departamento de Química Inorgánica. Instituto de Síntesis Química y Catálisis Homogénea (ISQCH), CSIC-Universidad de Zaragoza. C/ Pedro Cerbuna 12, E-50009 Zaragoza, Spain. <u>gimeno@unizar.es</u>

1. Characterisation of final products

Figure S1. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-4- (trifluoromethyl)aniline (3a).



Figure S2. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,5-difluoroaniline (**3b**).



Figure S3. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,5-difluoroaniline (**3b**).



Figure S4. ¹⁹F{¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,5-difluoroaniline (**3b**).



Figure S5. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,4,5-trifluoroaniline (3c).



Figure S6. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,4,5-trifluoroaniline (**3c**).



Figure S7. ¹⁹F{¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,4,5-trifluoroaniline (**3c**).



Figure S8. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-2,3,4,5,6-pentafluoroaniline (**3d**).

-140 f1 (ppm) -150

-170

-160

-180

-190

-200

-210

-70

-80

-90

-100

-110

-120

-130



Figure S9. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-2,3,4,5,6-pentafluoroaniline (**3d**).



Figure S10. ¹⁹F{¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-2,3,4,5,6-pentafluoroaniline (**3d**).

F1733



Figure S11. ¹H NMR (300 MHz, CD_3CN) spectrum of compound (*E*)-*N*-(1,3-diphenylallyl)-3,5-bis(trifluoromethyl)aniline (3e).



Figure S12. ¹H NMR (300 MHz, CD_3CN) spectrum of compound (*E*)-4-bromo-*N*-(1,3-diphenylallyl)aniline (**3f**).







Figure S14. ¹³C{¹H} APT NMR (101 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(3-bromophenyl)allyl)-4-(trifluoromethyl)aniline (3g).



S8

Figure S15. ¹H NMR (300 MHz, CD_3CN) spectrum of compound (*E*)-4-chloro-*N*-(1,3-diphenylallyl)aniline (**3h**).



Figure S16. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-4-(trifluoromethyl)aniline (4a).



Figure S17. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-4-(trifluoromethyl)aniline (4a).



Figure S18. ¹⁹F{¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-4-(trifluoromethyl)aniline (**4a**).



Figure S19. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-N-(1,3-di-p-tolylallyl)-4-(trifluoromethyl)aniline (**4b**).

Figure S20. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-di-*p*-tolylallyl)-4-(trifluoromethyl)aniline (**4b**).



Figure S21. ¹⁹F{¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-di-*p*-tolylallyl)-4-(trifluoromethyl)aniline (**4b**).



Figure S22. ¹H NMR (400 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-3,4-dichloroaniline (**4c**).



Figure S23. ¹³C{¹H} APT NMR (101 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-3,4-dichloroaniline (4c).



Figure S24. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-bromophenyl)allyl)-2-(*tert*-butyl)aniline (**4d**).



Figure S25. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(1,3-bis(4-chlorophenyl)allyl)-3-(*tert*-butyl)aniline (4d).



Figure S26. ¹H NMR (400 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(3-phenyl-1-(thiophen-2-yl)allyl)-4-(trifluoromethyl)aniline (4e).



Figure S27. ¹⁹F{¹H} NMR (376.5 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(3-phenyl-1-(thiophen-2-yl)allyl)-4-(trifluoromethyl)aniline (**4e**).



Figure S28. ¹H NMR (300 MHz, CD₃COCD₃) spectrum of compound (*E*)-*N*-(4-phenylbut-3-en-2-yl)-4-(trifluoromethyl)aniline (**4f**).



Figure S29. ¹³C{¹H} APT NMR (101 MHz, CD₃CN) spectrum of compound (*E*)-*N*-(4-phenylbut-3-en-2-yl)-4-(trifluoromethyl)aniline (4f).



Figure S30. ¹⁹F {¹H} NMR (282.4 MHz, CD₃COCD₃) spectrum of compound (*E*)-*N*-(4-phenylbut-3-en-2-yl)-4-(trifluoromethyl)aniline (4f).



Figure S31. COSY (300 MHz, CD₃COCD₃) spectrum of compound (*E*)-*N*-(4-phenylbut-3-en-2-yl)-4-(trifluoromethyl)aniline (**4f**).



Figure S32. ¹H NMR (300 MHz, CD₃CN) spectrum of compound *N*-(cyclohex-2-en-1-yl)-4- (trifluoromethyl)aniline (**4g**).



Figure S33. ¹H NMR (300 MHz, CD₃CN) spectrum of compound *N*-(2-ethylidenecyclohexyl)-4-(trifluoromethyl)aniline (**4h**).



Figure S34. ¹⁹F {¹H} NMR (282.4 MHz, CD₃CN) spectrum of compound *N*-(2-ethylidenecyclohexyl)-4-(trifluoromethyl)aniline (**4h**).

 $<^{-61.12}_{-61.14}$



Figure S35. ¹H NMR (300 MHz, CD_3CN) spectrum of compound (*E*)-*N'*-(1,3-diphenylallyl)benzohydrazide (**6a**).



Figure S36. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (E)-N'-(1,3-diphenylallyl)-4-nitrobenzohydrazide (6b).



Figure S37. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N*'-(1,3-diphenylallyl)-4-nitrobenzohydrazide (**6b**).



Figure S38. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-N'-(1,3-diphenylallyl)-4-methoxybenzohydrazide (**6c**).



Figure S39. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N'*-(1,3-diphenylallyl)-4-methoxybenzohydrazide (**6c**).



Figure S41. ${}^{13}C{}^{1}H$ APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-*N'*-(1,3-diphenylallyl)octanehydrazide (6d).



Figure S42. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-1*H*-indole (8a).



Figure S43. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-2-methyl-1*H*-indole (**8b**).



Figure S44. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-1-methyl-1*H*-indole (**8c**).



Figure S45. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-5-chloro-3-(1,3-diphenylallyl)-1*H*-indole (**8d**).



Figure S46. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-5-fluoro-1*H*-indole (**8e**).



Figure S47. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-1*H*-indole-4-carbonitrile (**8f**).



Figure S48. ¹³C{¹H} APT NMR (75 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-diphenylallyl)-1*H*-indole-4-carbonitrile (**8f**).



S25

Figure S49. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-bis(4-chlorophenyl)allyl)-1*H*-indole (**8g**).



Figure S50. ¹H NMR (300 MHz, CD₃CN) spectrum of compound (*E*)-3-(1,3-bis(4-chlorophenyl)allyl)-1*H*-indole (**8h**).



Figure S51. ¹H NMR (300 MHz, CDCl₃) spectrum of compound (E)-(3-(benzyloxy)prop-1-ene-1,3-diyl)dibenzene (10a).



Figure S52. ¹H NMR (400 MHz, CDCl₃) spectrum of compound (*E*)-hexa-1,5-diene-1,3-diyldibenzene (**10b**).





Figure S53. ¹H NMR (300 MHz, CDCl₃) spectrum of compound *tert*-butyl (E)-(1,3-diphenylallyl)carbamate (**10c**).

Figure S54. ¹H NMR (400 MHz, $CDCl_3$) spectrum of compound benzyl (*E*)-(1,3-diphenylallyl)carbamate (10d).



Figure S55. ¹H NMR (300 MHz, CDCN₃) spectrum of compound (*E*)-(3-azidoprop-1-ene-1,3-diyl)dibenzene (10e).



Figure S56. ¹H NMR (300 MHz, CDCN₃) spectrum of compound (*E*)-N-(1,3-diphenylallyl)benzamide (**10f**).



Figure S57. ¹H NMR (300 MHz, CDCN₃) spectrum of compound (E)-N-(1,3-diphenylallyl)-4-methylbenzenesulfonamide (10g).



Figure S58. ¹H NMR (300 MHz, CDCN₃) spectrum of compound (E)-4-(1,3-diphenylallyl)-N,N-dimethylaniline (**10h**).



2. Mechanistic assays

Figure S59. Reaction starting from alcohol 1j.



Figure S60. Reaction starting from alcohol 1k.

